Please login to the form below

Not currently logged in
Email:
Password:

COPD

This page shows the latest COPD news and features for those working in and with pharma, biotech and healthcare.

Novartis first to benefit from NICE advice on ‘patient preference’

Novartis first to benefit from NICE advice on ‘patient preference’

The advice was provided to Novartis, and looked at a patient preference study for people with respiratory condition chronic obstructive pulmonary disease (COPD). ... The aim is to support the development of new products to treat COPD patients.

Latest news

  • Advair generics and acquisitions to hit GSK in 2019 Advair generics and acquisitions to hit GSK in 2019

    These include three-drug COPD product Trelegy which realised £156m ($202m) for the year and Nucala, rising 64% to £563m ($729m) in the year.

  • GSK’s Advair Diskus faces first generic in US GSK’s Advair Diskus faces first generic in US

    The FDA approved Mylan’s version of the asthma and chronic obstructive pulmonary disease (COPD) brand yesterday, putting around $1bn in Advair sales at risk of steep decline. ... It has also given GSK a bit more time to advance its three-drug COPD

  • Circassia seeks shift to AIM after failing LSE criteria Circassia seeks shift to AIM after failing LSE criteria

    The Oxford-based company is buying US commercial rights to AstraZeneca’s chronic obstructive pulmonary disease (COPD) medicine Tudorza (aclidinium bromide), a drug that the two companies have partnered since 2017.

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    of the world’s asthma and chronic obstructive pulmonary disease (COPD) medicines.

  • Digital Trials Digital Trials

    In a recent COPD simulation, the study protocol, IRB, sensor selection, app development, recruitment, data generation and analysis were all undertaken within a five-month period. ... The devices were selected based on the endpoints that had been

More from news
Approximately 69 fully matching, plus 205 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

  • Open minds for open innovation Open minds for open innovation

    And a couple of years ago, Novartis and the COPD Foundation’s crowd-shaped project won Communique’s Innovation in Healthcare Communications Award!

  • Significant figures Significant figures

    NTM is a rare progressive, destructive infection that’s normally found in addition to pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or bronchiectasis.

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its ... The category has also seen the recent introduction of a major drug class

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    Combine asthma with other respiratory diseases, including chronic obstructive pulmonary disease (COPD), and it contributes to more than 4 million deaths every single year, a stagnated figure that has seen no ... This year, Circassia established a

More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Synergy Vision

    In light of today (18th November 2015) being World COPD Day, it’s never too late to raise further awareness on this disease. ... Many people suffer with Chronic Obstructive Pulmonary Disease (COPD), and many others are not aware of signs meaning they

  • Our nursing heroes

    For one chronic obstructive pulmonary disease (COPD) patient in the US, it meant more time with his grandchild. ... I really believe what we do with COPD patients in their own homes as clinical educators is making a big difference to their lives.”  .

  • Big wins for Frontera at the 2016 PM Awards

    This provides healthcare professionals with a life-action experience of what COPD patients go through on a daily basis.  .

  • Frontera wins at IPA Best of Health 2016

    The Silver was awarded for ‘Breathing is everything’, an interactive video created for healthcare professionals that offers a live-action experience of what COPD patients go through on a daily basis.

  • A Bitter Pill?

    as asthma and COPD, where inhalers are the most effective way to deliver medications to the target, this is particularly relevant because success is so dependent on good technique and some

More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics